

Manning AL, Dyson NJ: RB: mitotic implications of a tumour suppressor. *Nat Rev Cancer* 12:220–6, 2012. [In addition to the well established roles of RB in control of cell cycle progression and proliferation, this review describes other emerging tumor suppressive functions, such as maintenance of genomic stability]

Roy R, Chun J, Powell SN: BRCA1 and BRCA2: different roles in a common pathway of genome protection. *Nat Rev Cancer* 12:68–78, 2012. [A discussion of the concerted roles of the BRCA1 and BRCA2 tumor suppressor proteins in protecting the genome from double-strand DNA damage during DNA replication]

Song MS, Salmena L, Pandolfi PP: The functions and regulation of the PTEN tumour suppressor. *Nat Rev Mol Cell Biol* 13:283–96, 2012. [A detailed discussion of the tumor suppressive role of the lipid phosphatase PTEN]

### Cancer Cell Metabolism

Ward PS, Thompson CB: Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. *Cancer Cell* 21:297–308, 2012. [A review making the case that altered cancer metabolism is a fundamental hallmark of cancer cells]

### Autophagy

Lozy F, Karantza V: Autophagy and cancer cell metabolism. *Semin Cell Dev Biol* 23:395–401, 2012. [A discussion of how cellular metabolism and autophagy may contribute to the ability of cancer cells to adapt to environmental stressors and survive radiation and chemotherapy]

Mah LY, Ryan KM: Autophagy and cancer. *Cold Spring Harb Perspect Biol* 4:a008821, 2012. [A review of the possible interplay between autophagy and various aspects of tumor suppression, including cellular responses to nutrient and hypoxic stress, control of programmed cell death, and tumor-associated immune responses]

### Evasion of Apoptosis

Kilbride SM, Prehn JH: Central roles of apoptotic proteins in mitochondrial function. *Oncogene* 32:2703–11, 2013. [A review focusing on the mechanistic roles of pro-apoptotic members of the BCL-2 family in controlling mitochondrial activity and the implications of these activities for cancer cell biology]

Llambi F, Green DR: Apoptosis and oncogenesis: give and take in the BCL-2 family. *Curr Opin Genet Dev* 21:12–20, 2011. [A discussion of the complex and sometimes paradoxical roles of BCL-2 family members in cancer]

### Cancer Stem Cells

Magee JA, Piskounova E, Morrison SJ: Cancer stem cells: impact, heterogeneity, and uncertainty. *Cancer Cell* 21:283–96, 2012. [A critical review of the cancer stem cell model, with an eye towards its applicability to genetically and epigenetically heterogeneous human cancers]

Martinez P, Blasco MA: Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. *Nat Rev Cancer* 11:161–76, 2011. [A review discussing the role of telomeric proteins in immortalization of cancer cells and other emerging non-telomeric functions that may also contribute to oncogenesis]

### Angiogenesis

Bottsford-Miller JN, Coleman RL, Sood AK: Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies. *J Clin Oncol* 30:4026–34, 2012. [A discussion of how tumors escape from anti-angiogenic therapy and possible solutions to this limitation]

Fokas E, McKenna WG, Muschel RJ: The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. *Cancer Metastasis Rev* 31:823–42, 2012. [A discussion of the pro-oncogenic role of the tumor microenvironment in cancer and its implications for development of new therapies]

### Invasion and Metastasis

Spano D, Heck C, De Antonellis P, et al: Molecular networks that regulate cancer metastasis. *Semin Cancer Biol* 22:234–49, 2012. [A review that addresses some of the genetic events and critical factors that contributes to acquisition of the metastatic phenotype during oncogenesis]

Tiwari N, Gheldof A, Tatari M, et al: EMT as the ultimate survival mechanism of cancer cells. *Semin Cancer Biol* 22:194–207, 2012. [A

far-ranging discussion of the possible roles of epithelial-mesenchymal transition in metastasis and other cancer hallmarks]

### Evasion of Host Defense

Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* 366:2455–65, 2012. Also, Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 366:2443–54, 2012. [Two back-to-back landmark papers describing the anti-cancer activity of antibodies that interfere with the activity of PD-1, a signaling receptor that inhibits T cell function]

### Cancer Enabling Inflammation

Coussens LM, Zitvogel L, Palucka AK: Neutralizing tumor-promoting chronic inflammation: a magic bullet? *Science* 339:286–91, 2013. [A discussion of clinical and experimental studies describing protumorigenic roles for immune cells that elicit cancer-associated inflammation]

De Palma M, Lewis CE: Macrophage regulation of tumor responses to anticancer therapies. *Cancer Cell* 23:277–86, 2013. [A discussion of the pro- and anti-oncogenic effects of different subsets of tumor-associated macrophages]

Hanahan D, Coussens LM: Accessories to the crime: functions of cells recruited to the tumor microenvironment. *Cancer Cell* 21:309–22, 2012. [A detailed discussion of the possible roles of stromal cells in aiding and abetting cancer cells]

### Chromosomal Aberrations

Forment JV, Kaidi A, Jackson SP: Chromothripsis and cancer: causes and consequences of chromosomal shattering. *Nat Rev Cancer* 12:663–70, 2012. [A review describing how chromothripsis occurs and its potential diagnostic, prognostic and therapeutic implications in cancer]

Gostissa M, Alt FW, Chiarle R: Mechanisms that promote and suppress chromosomal translocations in lymphocytes. *Annu Rev Immunol* 29:319–50, 2011. [A discussion of pathogenic insights gleaned from experimental models of oncogenic chromosomal translocations in lymphocytes]

### Epigenetics and Cancer

Baylin SB, Jones PA: A decade of exploring the cancer epigenome - biological and translational implications. *Nat Rev Cancer* 11:726–34, 2011. [A discussion of recent discoveries that link epigenetic abnormalities in cancer to mutations in genes that control DNA methylation, the packaging and the function of DNA in chromatin, and metabolism]

Lindsley RC, Ebert BL: Molecular pathophysiology of myelodysplastic syndromes. *Annu Rev Pathol* 30:3376–82, 2012. [A review of the pervasive role of epigenetic abnormalities in this group of myeloid malignancies]

You JS, Jones PA: Cancer genetics and epigenetics: two sides of the same coin? *Cancer Cell* 22:9–20, 2012. [A review discussing the origins and interplay of mutations and epigenetic aberrations in cancer cells]

### Non-coding RNAs

Esteller M: Non-coding RNAs in human disease. *Nat Rev Genet* 12:861–74, 2011. [A review that discusses the roles of various classes of non-coding RNAs in human disease, including cancer]

Lujambio A, Lowe SW: The microcosmos of cancer. *Nature* 482:347–55, 2012. [A discussion of the roles of micro-RNAs in cancer]

### Environmental Carcinogens

Berger MF, Hodis E, Heffernan TP, et al: Melanoma genome sequencing reveals frequent PREX2 mutations. *Nature* 485:502–6, 2012. [A study that describes and quantifies the mutational impact of sun-exposure on melanoma genomes]

Pleasant ED, Stephens PJ, O'Meara S, et al: A small-cell lung cancer genome with complex signatures of tobacco exposure. *Nature* 463:184–90, 2010. [A study that describes and quantifies the mutational impact of carcinogens in tobacco smoke on lung cancer genomes]

### Microbial Carcinogenesis

Cabibbo G, Maida M, Genco C, et al: Causes of and prevention strategies for hepatocellular carcinoma. *Semin Oncol* 39:374–83, 2012. [A discussion of the various environmental factors implicated in hepatocellular carcinoma, including hepatitis viruses]

Magrath I: Epidemiology: clues to the pathogenesis of Burkitt lymphoma. *Br J Haematol* 156:744–56, 2012. [A discussion of the roles